Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Evolus Inc (EOLS) today and set a price target of $35. The company’s shares opened today at $24.38.
Chen noted:
“. Post a solid quarter of execution and ahead of what we expect to be a better-than-expected launch of Jeuveau, we are reiterating our OW rating and 12-month price target of $35. We think Jeuveau’s value proposition is underappreciated and that it will pick up more market share than anticipated. Therefore, the U.S. and other launches should drive EOLS’s stock higher, in our view.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 12.1% and a 41.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.
Evolus Inc has an analyst consensus of Strong Buy, with a price target consensus of $33.20.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.50 and a one-year low of $6.80. Currently, Evolus Inc has an average volume of 1.23M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded in November, 2012 and is headquartered in Newport Beach, CA.
